Skip to main content
Log in

Glatiramer acetate best bet in RRMS?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Journal of Managed Care Pharmacy 13: 245-261, No. 3, Apr 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glatiramer acetate best bet in RRMS?. Pharmacoecon. Outcomes News 531, 5 (2007). https://doi.org/10.2165/00151234-200705310-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705310-00008

Keywords

Navigation